The 2014 American College of Cardiology ACC/American Heart Association Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes Ten Contemporary Recommendations to Aid Clinicians in Optimizing Patient Outcomes

Ezra A. Amsterdam, University of California Davis
Nanette K Wenger, Emory University

Journal Title: Clinical Cardiology
Volume: Volume 38, Number 2
Publisher: Wiley Open Access: Various Creative Commons Licenses | 2015-02-01, Pages 121-123
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1002/clc.22354
Permanent URL: https://pid.emory.edu/ark:/25593/v39xq

Final published version: http://dx.doi.org/10.1002/clc.22354

Copyright information:
© 2015 Wiley Periodicals, Inc.

Accessed March 15, 2020 12:44 PM EDT
The 2014 American College of Cardiology ACC/American Heart Association Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

Ten Contemporary Recommendations to Aid Clinicians in Optimizing Patient Outcomes

Ezra A. Amsterdam, MD, FACC, FAHA and Nanette K. Wenger, MD, MACC, MACP

Division of Cardiovascular Medicine (Amsterdam), Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California and Department of Medicine, Division of Cardiology (Wenger), Emory University School of Medicine, Atlanta, Georgia

The new title, “Non–ST-Elevation Acute Coronary Syndromes (NSTE-ACS),” for this full revision of the 2007 American College of Cardiology Foundation/American Heart Association guideline titled “Unstable Angina/Non–ST-Elevation Myocardial Infarction,” more concisely emphasizes the continuum between unstable angina (UA) and non–ST-elevation myocardial infarction (NSTEMI). They can be indistinguishable at presentation and therefore are considered together using the terminology non–ST-elevation acute coronary syndromes. Approximately 70% of patients with an acute coronary syndrome have an NSTE-ACS, comprising more than 625,000 patients annually.1

In the appropriate clinical context, if cardiac biomarkers are normal, the patient is deemed to have UA; if troponins are elevated, the patient is considered to have an NSTEMI.2 Additional new terminology relates to the initial strategy for management of patients with NSTE-ACS. The initial treatment pathways have been recategorized into, as previously, an early invasive strategy, seeking to rapidly risk stratify patients by angiographic assessment of their coronary anatomy with intent to perform revascularization when appropriate. The new designation, an ischemia-guided strategy, has replaced the previous term, initial conservative therapy, to more clearly convey the physiologic rationale of this approach. Ischemia-guided strategy involves guideline-directed medical therapy, with coronary angiography only if the patient experiences refractory or recurrent ischemic symptoms or develops hemodynamic instability.

Finally, this guideline highlights the third universal definition of myocardial infarction,3 which differentiates myocardial infarction caused by a primary coronary artery process, such as spontaneous plaque rupture, from a myocardial infarction related to reduced myocardial oxygen supply and/or increased demand in the absence of a direct coronary artery process.

1. Patients with chest pain or other symptoms suggesting acute coronary syndromes (ACS) should have 12-lead electrocardiography (ECG) performed and evaluated within 10 minutes of arrival at an emergency facility, and serial ECGs performed to detect ischemic changes. Serial cardiac troponin I or T levels (using a contemporary assay) should be obtained at presentation and at 3 to 6 hours after symptom onset. Risk scores can help assess prognosis. In patients with symptoms consistent with ACS without objective evidence of myocardial ischemia (nonischemic ECG and normal cardiac troponin levels), noninvasive imaging is reasonable before emergency department discharge or within 72 hours after discharge.

2. Standard initial medical therapies include: supplemental oxygen for arterial oxygen saturation <90% or respiratory distress; sublingual nitroglycerin; oral β-blocker therapy within the first 24 hours in the absence of heart failure, low output state, increased risk for cardiogenic shock or other contraindications to β-blockade; nondihydropyridine calcium channel blocker for continuing or recurrent ischemia and contraindication to β-blockade (in the absence of clinically significant left ventricular dysfunction). Nonsteroidal anti-inflammatory drugs (except aspirin) should not be initiated and should be discontinued during the hospitalization for NSTE-ACS because of the increased risk of major adverse cardiac events associated with their use.

3. Initial antplatelet/anticoagulant therapy includes: 325-mg chewable aspirin at presentation, followed by a daily maintenance dose of aspirin at 81 to 126 mg daily. A P2Y12 inhibitor (clopidogrel or ticagrelor) in addition to aspirin for up to 12 months in patients treated with either an early-invasive or ischemia-guided strategy. In addition to antplatelet therapy, parenteral anticoagulation is indicated with enoxaparin, bivalirudin, fondaparinux, or unfractionated heparin.

4. A high-intensity statin should be initiated or continued in all patients without contraindications. Angiotensin-converting enzyme inhibitors should be started and continued indefinitely with a left ventricular ejection fraction ≤40%, or hypertension, diabetes, or stable chronic kidney disease unless contraindicated.

The authors have no funding, financial relationships, or conflicts of interest to disclose.
**Figure 1.** Algorithm for management of patients with definite or likely non–ST-elevation acute coronary syndromes (NSTE-ACS). Abbreviations: ASA, American Society of Anesthesiologists; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; GPI, glycoprotein inhibitor; LOE, level of evidence; PCI, percutaneous coronary intervention; pts, patients; UFH, unfractionated heparin. Reprinted with permission.

1. **Ischemia-Guided Strategy**
   - **Initiate DAPT and Anticoagulant Therapy**
     1. ASA (Class I; LOE: A)
     2. P2Y12 inhibitor (in addition to ASA) (Class I; LOE: B): Clopidogrel or Ticagrelor
     3. Anticoagulant:
        - UFH (Class I; LOE: B) or Enoxaparin (Class I; LOE: A) or Fondaparinux (Class I; LOE: B)

2. **Early Invasive Strategy**
   - **Initiate DAPT and Anticoagulant Therapy**
     1. ASA (Class I; LOE: A)
     2. P2Y12 inhibitor (in addition to ASA) (Class I; LOE: B): Clopidogrel or Ticagrelor
     3. Anticoagulant:
        - UFH (Class I; LOE: B) or Enoxaparin (Class I; LOE: A) or Fondaparinux† (Class I; LOE: B) or Bivalirudin (Class I; LOE: B)

     Can consider GPI in addition to ASA and P2Y12 inhibitor in high-risk (e.g., troponin positive) pts (Class IIb; LOE: B):
     - Eptifibatide
     - Tirofibain

3. **Medical therapy chosen based on cath findings**

4. **PCI With Stenting**
   - **Initiate/continue antiplatelet and anticoagulant therapy**
     1. ASA (Class I; LOE: B)
     2. P2Y12 inhibitor (in addition to ASA) (Class I; LOE: B): Clopidogrel or Ticagrelor or Prasugrel
     3. GPI (if not treated with bivalirudin at time of PCI)
        - High-risk features, not adequately pretreated with clopidogrel (Class I; LOE: A)
        - High-risk features adequately pretreated with clopidogrel (Class IIa; LOE: B)
     4. Anticoagulant:
        - Enoxaparin (Class I; LOE: A) or Bivalirudin (Class I; LOE: B) or Fondaparinux† as the sole anticoagulant (Class III: Harm; LOE: B) or UFH (Class I; LOE: B)

5. **CABG**
   - **Initiate/continue ASA therapy and discontinue P2Y12 and/or GPI therapy**
     1. ASA (Class I; LOE: B)
     2. Discontinue clopidogrel/ticagrelor 5 d before and prasugrel at least 7 d before elective CABG
     3. Discontinue clopidogrel/ticagrelor up to 24 h before urgent CABG (Class I; LOE: B; May perform urgent CABG ≤5 d after clopidogrel/ticagrelor and ≤7 d after prasugrel discontinued
     4. Discontinue eptifibatide/tirofibain at least 2–4 h before and abciximab ≥12 h before CABG (Class I; LOE: B)

6. **Late Hospital/Posthospital Care**
   - **Initiate/continue ASA indefinitely (Class I; LOE: A)
   - P2Y12 inhibitor (clopidogrel or ticagrelor), in addition to ASA, up to 12 mo if medically treated (Class I; LOE: B)
   - P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor), in addition to ASA, at least 12 mo if treated with coronary stenting (Class I; LOE: B)
5. An algorithm (Figure 1) details the components of an early invasive strategy or an ischemia-guided strategy. An early invasive strategy is indicated for patients with refractory angina or hemodynamic or electrical instability and those at elevated risk for clinical events. An early invasive strategy is not recommended for patients with extensive comorbidities (eg, hepatic, renal, or pulmonary failure; cancer) in whom the risks of revascularization and comorbidity conditions are likely to outweigh the benefits of revascularization. An ischemia-guided strategy is appropriate for low-risk score patients (Thrombolysis In Myocardial Infarction or Global Registry of Acute Coronary Events), low-risk troponin-negative women, and by patient or clinician preference in the absence of high-risk features. When an ischemia-guided strategy is chosen, noninvasive stress testing is recommended prior to hospital discharge to detect severe ischemia occurring at a low-stress threshold.

6. Patients undergoing percutaneous coronary intervention (PCI) should be treated with a P2Y12 inhibitor: clopidogrel, prasugrel, or ticagrelor. Discharge planning should include detailed patient education about symptoms, lifestyle interventions, standard medication with dual antiplatelet therapy, cholesterol management, referral to cardiac rehabilitation, timely follow-up with the healthcare team, and influenza and pneumococcal vaccines.

7. NSTE-ACS patients with prior revascularization PCI or coronary artery bypass grafting should receive antiplatelet and anticoagulant therapy and be strongly considered for an early invasive strategy because of their increased risk. Medical treatment in the acute phase of NSTE-ACS and decisions to perform stress testing, angiography, and revascularization should be similar in patients with and without diabetes mellitus.

8. Patients who develop NSTE-ACS following noncardiac surgery should receive guideline-directed medical therapy, with additional management directed at the underlying cause of the pathophysiologic process.

9. Older patients with NSTE-ACS, because of their high-risk status, should be treated with guideline-directed medical therapy and an early invasive strategy with revascularization as appropriate; pharmacotherapy should be individualized and dose adjusted by weight and creatinine clearance to reduce adverse events. Management decisions should be patient centered, incorporating patient preferences, comorbidities, functional and cognitive status, and life expectancy.

10. Women with NSTE-ACS should be managed with the same pharmacologic therapy as men for acute care and secondary prevention, with attention to weight and/or renally calculated doses of antiplatelet and anticoagulant agents to reduce bleeding risk. Women with NSTE-ACS and high-risk features (eg, troponin positive) should undergo an early invasive strategy.

Despite landmark advances in the care of patients with NSTE-ACS, emerging diagnostic and therapeutic strategies have posed new challenges. Evidence-based decisions will require comparative effectiveness studies of available and novel potent antithrombotic and anticoagulant drugs that reduce major adverse cardiac outcomes but increase bleeding risk. The paradox of newer and more potent antithrombotic and anticoagulant therapy requires a balance between risk and benefits, particularly addressing measurement of absolute cardiac troponin change rather than traditional analysis of relative alterations.

More than half of the NSTE-ACS mortality occurs in older patients, with this high-risk cohort increasing as our population ages. An unmet need is to more clearly distinguish their optimal management strategies. An appreciable number of NSTE-ACS patients have angiographically normal or nonobstructive coronary artery disease; women predominate in this population and their prognosis is not benign. Clinical advances are predicated on clarification of the pathophysiology of this challenging syndrome.

A fundamental aspect of all clinical practice guidelines is that these evidence-based documents cannot encompass all clinical circumstances, nor can they replace the judgment of individual physicians in the management of each patient. The science of medicine is rooted in evidence and the art of medicine is based on the application of this evidence to the individual NSTE-ACS patient.

References